Campbell & CO Investment Adviser LLC acquired a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,190 shares of the medical instruments supplier’s stock, valued at approximately $246,000.
A number of other hedge funds have also recently added to or reduced their stakes in ANGO. Hartford Investment Management Co. purchased a new stake in AngioDynamics during the second quarter worth $248,000. Peregrine Capital Management LLC purchased a new stake in AngioDynamics during the second quarter worth $12,133,000. First Quadrant L P CA raised its stake in AngioDynamics by 5.9% in the second quarter. First Quadrant L P CA now owns 112,463 shares of the medical instruments supplier’s stock worth $1,823,000 after buying an additional 6,312 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in AngioDynamics by 6.9% in the second quarter. Louisiana State Employees Retirement System now owns 13,900 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 900 shares in the last quarter. Finally, Fenimore Asset Management Inc. raised its stake in AngioDynamics by 9.1% in the second quarter. Fenimore Asset Management Inc. now owns 579,225 shares of the medical instruments supplier’s stock worth $9,389,000 after buying an additional 48,150 shares in the last quarter. Institutional investors and hedge funds own 85.84% of the company’s stock.
AngioDynamics, Inc. (NASDAQ ANGO) traded up 0.55% during trading on Friday, hitting $16.36. 157,969 shares of the company were exchanged. The firm’s 50 day moving average price is $16.21 and its 200-day moving average price is $16.17. The stock has a market capitalization of $598.45 million, a PE ratio of 119.42 and a beta of 1.15. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.18.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The company had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The firm’s revenue was down 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 earnings per share. Equities analysts predict that AngioDynamics, Inc. will post $0.67 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/08/12/campbell-co-investment-adviser-llc-buys-shares-of-15190-angiodynamics-inc-nasdaqango-updated.html.
A number of analysts have recently issued reports on ANGO shares. Canaccord Genuity reaffirmed a “hold” rating and set a $16.50 price target on shares of AngioDynamics in a report on Wednesday, May 31st. Cantor Fitzgerald raised their price target on shares of AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. Barclays PLC dropped their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 19th. Zacks Investment Research downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Thursday, July 20th. Finally, BidaskClub downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. AngioDynamics currently has a consensus rating of “Hold” and a consensus target price of $18.50.
In other news, CEO James C. Clemmer purchased 5,000 shares of the company’s stock in a transaction on Friday, July 21st. The stock was bought at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the purchase, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James C. Clemmer purchased 20,000 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were purchased at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the purchase, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The disclosure for this purchase can be found here. Insiders have acquired 25,316 shares of company stock valued at $396,806 over the last 90 days. 1.88% of the stock is currently owned by insiders.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.